The above results indicated that PTX3 could be considered a therapeutic target for high-risk patients with OHSS and highlighted the potential of VD3 as a therapeutic strategy for the aforementioned patients. The gene discussed is PTX3; the disease is ovarian hyperstimulation syndrome.